Cipla spurts on inking MoU with Russian firm for HIV, Hepatitis C drugs

20 Jun 2016 Evaluate

Cipla is currently trading at Rs. 487.40, up by 1.85 points or 0.38% from its previous closing of Rs 485.55 on the BSE.

The scrip opened at Rs. 486.00 and has touched a high and low of Rs. 489.80 and Rs. 484.65 respectively. So far 28666 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 748.00 on 17-Aug-2015 and a 52 week low of Rs. 458.25 on 25-May-2016.

Last one week high and low of the scrip stood at Rs. 492.00 and Rs. 465.20 respectively. The current market cap of the company is Rs. 39053.43 crore.

The promoters holding in the company stood at 36.78%, while Institutions and Non-Institutions held 34.17% and 27.13% respectively.

Cipla, a global pharmaceutical company has signed a Memorandum of Understanding (MoU) with Russia’s National Immunobiological Company to innovative antiviral medical products for HIV and Hepatitis C treatment and to technology transfer and active pharmaceutical ingredients (API) manufacturing. New drugs production will help to change therapeutic regimens and substantially increase availability of drugs for Russian patients. By 2019 total market share for anti-HIV drugs will increase to 60%.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.

Cipla Share Price

1397.95 -36.65 (-2.55%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×